These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38616658)

  • 21. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).
    Martinez-Marti A; Felip E; Matito J; Mereu E; Navarro A; Cedrés S; Pardo N; Martinez de Castro A; Remon J; Miquel JM; Guillaumet-Adkins A; Nadal E; Rodriguez-Esteban G; Arqués O; Fasani R; Nuciforo P; Heyn H; Villanueva A; Palmer HG; Vivancos A
    Ann Oncol; 2017 Oct; 28(10):2451-2457. PubMed ID: 28961841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR-TKI rechallenge in patients with EGFR-mutated non-small-cell lung cancer who progressed after first-line osimertinib treatment: A multicenter retrospective observational study.
    Araki T; Kanda S; Obara M; Agatsuma T; Kakizaki Y; Hama M; Yamamoto H; Takada M; Yamamoto M; Matsuo A; Kondo D; Komatsu M; Sonehara K; Tateishi K; Hanaoka M; Koizumi T
    Respir Investig; 2024 Mar; 62(2):262-268. PubMed ID: 38245931
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
    Lee EJ; Oh SY; Lee YW; Kim JY; Kim MJ; Kim TH; Lee JB; Hong MH; Lim SM; Baum A; Woelflingseder L; Engelhardt H; Petronczki M; Solca F; Yun MR; Cho BC
    Clin Cancer Res; 2024 Apr; 30(8):1582-1594. PubMed ID: 38330145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines.
    Ji W; Choi YJ; Kang MH; Sung KJ; Kim DH; Jung S; Choi CM; Lee JC; Rho JK
    Cells; 2020 Dec; 9(12):. PubMed ID: 33287368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
    Park W; Wei S; Xie CL; Han JH; Kim BS; Kim B; Jin JS; Yang ES; Cho MK; Ryu D; Yang HX; Bae SJ; Ha KT
    Exp Mol Med; 2024 May; 56(5):1137-1149. PubMed ID: 38689087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an
    Nishihara S; Yamaoka T; Ishikawa F; Ohmori T; Ando K; Kusumoto S; Kishino Y; Manabe R; Hasebe Y; Sagara H; Yoshida H; Tsurutani J
    Cells; 2022 Jul; 11(14):. PubMed ID: 35883645
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stepwise prolongation of overall survival from first to third generation EGFR-TKIs for EGFR mutation-positive non-small-cell lung cancer: the Tokushukai REAl-world Data project (TREAD 01).
    Uryu K; Imamura Y; Shimoyama R; Mase T; Fujimura Y; Hayashi M; Ohtaki M; Otani K; Hibino M; Horiuchi S; Fukui T; Fukai R; Chihara Y; Iwase A; Yamada N; Tamura Y; Harada H; Shinozaki N; Tsuya A; Fukuoka M; Minami H
    Jpn J Clin Oncol; 2024 Mar; 54(3):319-328. PubMed ID: 37997468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer.
    Chen Z; Vallega KA; Wang D; Quan Z; Fan S; Wang Q; Leal T; Ramalingam SS; Sun SY
    J Exp Med; 2024 Nov; 221(11):. PubMed ID: 39297884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PIM1 kinase promotes EMT-associated osimertinib resistance via regulating GSK3β signaling pathway in EGFR-mutant non-small cell lung cancer.
    Zhou J; Wang X; Li Z; Wang F; Cao L; Chen X; Huang D; Jiang R
    Cell Death Dis; 2024 Sep; 15(9):644. PubMed ID: 39227379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
    Gen S; Tanaka I; Morise M; Koyama J; Kodama Y; Matsui A; Miyazawa A; Hase T; Hibino Y; Yokoyama T; Kimura T; Yoshida N; Sato M; Hashimoto N
    BMC Cancer; 2022 Jun; 22(1):654. PubMed ID: 35698083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sialyltransferase ST3GAL4 confers osimertinib resistance and offers strategies to overcome resistance in non-small cell lung cancer.
    Han R; Lin C; Lu C; Wang Y; Kang J; Hu C; Dou Y; Wu D; He T; Tang H; Zheng J; Li L; He Y
    Cancer Lett; 2024 Apr; 588():216762. PubMed ID: 38408602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
    Ballard P; Yates JW; Yang Z; Kim DW; Yang JC; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress KS; Jänne PA; Cross D
    Clin Cancer Res; 2016 Oct; 22(20):5130-5140. PubMed ID: 27435396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.
    Haratake N; Ozawa H; Morimoto Y; Yamashita N; Daimon T; Bhattacharya A; Wang K; Nakashoji A; Isozaki H; Shimokawa M; Kikutake C; Suyama M; Hashinokuchi A; Takada K; Takenaka T; Yoshizumi T; Mitsudomi T; Hata AN; Kufe D
    J Thorac Oncol; 2024 Mar; 19(3):434-450. PubMed ID: 37924972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. De Novo mutation in Epidermal growth factor receptor (EGFR)-D761Y responding to third generation tyrosine kinase inhibitor Osimertinib: A case report.
    Ding Y; Dong H; Li Y; Liu L; Cai Y; Wang Y; Tian S; Dai C
    Medicine (Baltimore); 2022 Jul; 101(29):e29332. PubMed ID: 35866776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer.
    Nakamura R; Yamada T; Tokuda S; Morimoto K; Katayama Y; Matsui Y; Hirai S; Ishida M; Kawachi H; Sawada R; Tachibana Y; Osoegawa A; Horinaka M; Sakai T; Yasuhiro T; Kozaki R; Yano S; Takayama K
    Cancer Lett; 2024 Aug; 598():217124. PubMed ID: 39059573
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN Alterations.
    Grazini U; Markovets A; Ireland L; O'Neill D; Phillips B; Xu M; Pfeifer M; Vaclova T; Martin MJ; Bigot L; Friboulet L; Hartmaier R; Cuomo ME; Barry ST; Smith PD; Floc'h N
    Clin Cancer Res; 2024 Sep; 30(18):4143-4154. PubMed ID: 38630555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
    Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
    Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib.
    Liu Y; Li Y; Ou Q; Wu X; Wang X; Shao YW; Ying J
    Lung Cancer; 2018 Apr; 118():1-5. PubMed ID: 29571986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired Resistance to Osimertinib in
    Bertoli E; De Carlo E; Del Conte A; Stanzione B; Revelant A; Fassetta K; Spina M; Bearz A
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.